Buy Stock In Gw Pharmaceuticals Page

: The acquisition included GW’s cannabinoid product platform and clinical-stage programs for additional indications such as autism, schizophrenia, and multiple sclerosis-related spasticity.

: Epidiolex was the first FDA-approved plant-derived cannabinoid medicine, used to treat severe forms of childhood-onset epilepsy like Dravet syndrome and Lennox-Gastaut syndrome. It reached over $500 million in annual net sales in 2020 and has continued to expand globally as Epidyolex in Europe. buy stock in gw pharmaceuticals

To invest in the GW Pharmaceuticals portfolio today, you would need to buy shares of its parent company, . To invest in the GW Pharmaceuticals portfolio today,

Investment Rationale for GW Pharmaceuticals (via Jazz Pharmaceuticals) : The deal was designed to accelerate double-digit

GW Pharmaceuticals pioneered the use of cannabis-derived medicines, most notably . Since the acquisition, this platform has become a cornerstone of the Jazz Pharmaceuticals business model.

: The deal was designed to accelerate double-digit revenue growth. In the months following the close, Jazz reported that newly acquired products like Epidiolex contributed significantly to its total net product sales. Considerations Before Buying